ScandiDos Announces Delta4 Discover™ Launch Plans at ASTRO Meeting

In-Vivo Dosimetry System Ensures Delivered Dose in Cancer Radiation Therapy

American Society for Radiation Oncology (ASTRO) 56th Annual Meeting

SAN FRANCISCO--()--Today at the American Society for Radiation Oncology (ASTRO) 56th Annual Meeting, ScandiDos AB [NASDAQ OMX First North: SDOS] announced its plans for launching Delta4 Discover™, a new product in its successful Delta4 dosimetry equipment platform. ScandiDos, worldwide leader in the development of advanced dosimetry and QA (Quality Assurance) products for cancer radiation therapy, said it has made excellent progress in Delta4 Discover’s development and expects to be able to launch it in the U.S. within the next few months, pending finalization of beta testing and FDA approval.

Delta4 Discover is an in-vivo dosimetry system that will provide tools for the measurement of the delivered dose of radiation during cancer radiation therapy, even for the most complex and demanding treatment methods, by independently verifying all dosage delivery parameters.

“Until now, nobody has been able to effectively and efficiently measure the actual delivered dose of radiation a patient receives on a daily basis to compare to the treatment plan,” commented Scandidos President and CEO Görgen Nilsson. “Delta4 Discover will be capable of doing just that. It will bring a new level of sophistication to dosimetry technology for cancer radiation therapy.”

Nilsson added that Delta4 Discover was designed with input from leading medical physicists. “Scandidos has done extensive research on the needs and wishes of radiation therapy teams around the world. This product has been designed with the necessary technology to meet those needs,” he said. “We’re very proud of our R&D on Delta4 Discover, and excited about its ability to increase the safety of patients and the confidence of radiation oncologists and physicists in their treatment QA.”

About Scandidos AB

Scandidos AB provides the quality assurance (QA) technology that ensures radiation doses in advanced radiation therapy are delivered to the patient in the quantity and manner that was intended. The company’s measurement systems and software are designed to meet QA requirements and provide validation of the new cancer radiation treatments being implemented in clinics around the world. ScandiDos was founded in 2002 and is headquartered in Uppsala, Sweden. The company operates worldwide, with a U.S. office in Madison, Wis. and a Chinese office in Beijing, and partners with Elekta, Varian and some 40 local distributors. ScandiDos has installed its dosimetry and QA systems in 40 countries. The company’s systems can be found in well-known cancer centers throughout the United States. More information about ScandiDos is available at http://www.scandidos.com

Contacts

Scandidos AB
Görgen Nilsson
Madison, Wis. office: 608-630-9415
Uppsala, Sweden office: +46 18 472 30 30
gorgen.nilsson@scandidos.com

Release Summary

ScandiDos AB announced plans for launching Delta4 Discover™, a new device that will measure the delivered dose of radiation during cancer radiation therapy, even for complex treatment methods.

Contacts

Scandidos AB
Görgen Nilsson
Madison, Wis. office: 608-630-9415
Uppsala, Sweden office: +46 18 472 30 30
gorgen.nilsson@scandidos.com